0001842952FALSE00018429522024-12-232024-12-23

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 23, 2024
Context Therapeutics Inc.
(Exact name of registrant as specified in its charter)
Delaware001-40654
86-3738787
(State of other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
2001 Market Street, Suite 3915, Unit #15
Philadelphia, Pennsylvania 19103
(Address of principal executive offices including zip code)
(267) 225-7416
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐        Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐        Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐        Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐        Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Title of each class
Trading
Symbol		Name of exchange
on which registered
Common StockCNTXThe Nasdaq Stock Market
$0.001 par value per share
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 8.01. Other Events.
On December 23, 2024, Context Therapeutics Inc. (the “Company”) sold 14,705,882 shares of its common stock, for aggregate gross proceeds of approximately $15 million. The shares were sold pursuant to a sales agreement with Leerink Partners LLC (the “Agent”) dated December 2, 2024. The Agent has informed the Company that the shares were purchased by MPM BioImpact LLC.


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: December 23, 2024Context Therapeutics Inc.
By: /s/ Martin A. Lehr
Name: Martin A. Lehr
Title: Chief Executive Officer

v3.24.4
Cover
Dec. 23, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Dec. 23, 2024
Entity Registrant Name Context Therapeutics Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-40654
Entity Tax Identification Number 86-3738787
Entity Address, Address Line One 2001 Market Street,
Entity Address, Address Line Two Suite 3915
Entity Address, Address Line Three Unit #15
Entity Address, City or Town Philadelphia
Entity Address, State or Province PA
Entity Address, Postal Zip Code 19103
City Area Code (267)
Local Phone Number 225-7416
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol CNTX
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity Central Index Key 0001842952
Amendment Flag false
Context Therapeutics (NASDAQ:CNTX)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Context Therapeutics Charts.
Context Therapeutics (NASDAQ:CNTX)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Context Therapeutics Charts.